跳至主要内容
临床试验/NCT05101330
NCT05101330撤回不适用

Impact of Bilingual Prescription Medication Labels on Medication Adherence and Medication Management Self-Efficacy Among Elderly Singaporeans: A Pilot Study

Singapore General Hospital2 个研究点 分布在 1 个国家开始时间: 2021年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Measuring change from Week 2 in Medication Adherence based on Rx Cap openings at Week 4. (Pilot Trial A)

研究概览

简要总结

The proposed study aims to provide preliminary data that will enable the conduct of a larger Randomized Controlled Trial (RCT) on the impact of bilingual Prescription Medication Labels (PMLs) on 3 medication-related outcomes - medication adherence, medication management self-efficacy, and PML understanding.

详细描述

The investigators will randomize 40 patients to Pilot Trial A or Pilot Trial B. Those in Pilot Trial A will be further randomized to Bilingual PMLs (intervention arm) or English PMLs (usual care arm) at 2 weeks post-recruitment, after assessing baseline level of the 3 medication-related outcomes; trial outcomes: difference in change, from baseline to 2 weeks post-randomization, in the 3 medication-related outcomes between the 2 arms. Those in Pilot Trial B will be further randomized to Bilingual PMLs or English PMLs immediately post-recruitment; trial outcomes: difference, at 2 weeks post-randomization, in the 3 medication-related outcomes between the 2 arms. This formative study will (1) assess the feasibility of administering the intervention, (2) refine protocols for study participant recruitment, engagement and retention, and (3) gain experience with and refine measurement of the outcomes for evaluating the intervention. The conduct of 2 pilot trials will allow us to choose the optimal trial design and determine variability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Singapore citizen/permanent resident
  • Aged 50 years and above
  • Just received a new (i.e., not received before) oral medication for a chronic disease
  • No moderate/severe cognitive impairment (5 or more correct responses on the Abbreviated Mental Test, AMT)
  • Not deaf (self-reported)
  • No binocular presenting near vision impairment (near visual acuity, with routinely used spectacles/lenses: at least 6/15 (0.40 logMAR) on the Landolt's C chart)
  • Able to speak at least 1 of the 4 official languages;
  • Unable to read in English but able to read another official language (as they will benefit the most from bilingual PMLs)
  • Assessed as non-adherent

排除标准

  • Patients who received, from the prescribing physician, a set of instructions for their new oral medication that does not match standard instructions (as the bilingual instructions for non-standard instructions would not be prepared for beforehand)

结局指标

主要结局

Measuring change from Week 2 in Medication Adherence based on Rx Cap openings at Week 4. (Pilot Trial A)

时间窗: Week 2 and Week 4 of Pilot Trial A

The Rx Cap Bluetooth smart cap automatically tracks medication usage every time it is opened. The data collected and stored within the Smart Cap will be imported at home visits with participants. Continuous (% adherence to prescribed regimen; 0-100%) and categorical variables (not at all; partially; fully) for medication adherence will be derived.

Assessing Medication Adherence based on Rx Cap openings at Week 2. (Pilot Trial B)

时间窗: Week 2 of Pilot Trial B

The Rx Cap Bluetooth smart cap automatically tracks medication usage every time it is opened. The data collected and stored within the Smart Cap will be imported at home visits with participants. Continuous (% adherence to prescribed regimen; 0-100%) and categorical variables (not at all; partially; fully) for medication adherence will be derived.

Assessing PML understanding at Week 2. (Pilot Trial B)

时间窗: Week 2 of Pilot Trial B

Respondents will be asked tailored questions (in their preferred language) specific to the instructions presented on their PML for the new oral medication.

Measuring change from Week 2 in Medication Adherence using the MedTake Assessment at Week 4. (Pilot Trial A)

时间窗: Week 2 and Week 4 of Pilot Trial A

MedTake Assessment is a self-reported measure for pharmacy staff when providing pharmaceutical care services, assessing patient adherence and knowledge to dose, dosage, indication, food or water co-ingestion, and regimen. A composite score (0-100%); higher \~ better) summarizes patient's ability to take medicine safely.

Assessing Medication Adherence using the MedTake Assessment at Week 2 (Pilot Trial B)

时间窗: Week 2 of Pilot Trial B

MedTake Assessment is a self-reported measure for pharmacy staff when providing pharmaceutical care services, assessing patient adherence and knowledge to dose, dosage, indication, food or water co-ingestion, and regimen. A composite score (0-100%); higher \~ better) summarizes patient's ability to take medicine safely.

Measuring change from Week 2 in Medication Adherence via Pill Count at Week 4. (Pilot Trial A)

时间窗: Week 2 and Week 4 of Pilot Trial A

A pill count, in context of the new oral medication, will be done. % adherence = ((quantity dispensed)-(quantity remaining))/ ((prescribed number of pills per day) x (no. of days between dispensing date and interview))

Measuring Medication management self-efficacy on the MUSE Scale at Week 2 (Pilot Trial B)

时间窗: Week 2 of Pilot Trial B

The 8-item Medication Understanding and Use Self-Efficacy Scale (MUSE), comprises of 2 subscales: (1) taking medication (4 items), and (2) learning about medication (4 items). Item scores (four-point Likert scale; strongly disagree (score 1), to, strongly agree (score=4)) will be summed for subscale (range: 4-16) and total scores (range: 8-32; higher score \~ greater level of medication management self-efficacy).

Measuring change from Week 2 in Medication Adherence on the Adherence to Refills and Medications Scale (ARMS) at Week 4. (Pilot Trial A)

时间窗: Week 2 and Week 4 of Pilot Trial A

ARMS is a validated self-reported medication-adherence scale intended for patients with chronic diseases. Its 12 questions consist of 2 subscales - adherence to refilling prescriptions and adherence with taking medications. Each item is structured using the Likert scale, with the following response options and corresponding scores: "none" (score of 1), "some" (score of 2), "most" (score of 3 ), or "all of the time" (score of 4). The range of possible total scores is 12 to 48. Lower scores indicate better adherence.

Assessing Medication Adherence via Pill Count at Week 2. (Pilot Trial B)

时间窗: Week 2 of Pilot Trial B

A pill count, in context of the new oral medication, will be done. % adherence = ((quantity dispensed)-(quantity remaining))/ ((prescribed number of pills per day) x (no. of days between dispensing date and interview))

Measuring change from Week 2 in Medication management self-efficacy on the MUSE Scale at Week 4. (Pilot Trial A)

时间窗: Week 2 and Week 4 of Pilot Trial A

The 8-item Medication Understanding and Use Self-Efficacy Scale (MUSE), comprises of 2 subscales: (1) taking medication (4 items), and (2) learning about medication (4 items). Item scores (four-point Likert scale; strongly disagree (score 1), to, strongly agree (score=4)) will be summed for subscale (range: 4-16) and total scores (range: 8-32; higher score \~ greater level of medication management self-efficacy).

Measuring change from Week 2 in PML understanding at Week 4. (Pilot Trial A)

时间窗: Week 2 and Week 4 of Pilot Trial A

Respondents will be asked tailored questions (in their preferred language) specific to the instructions presented on their PML for the new oral medication.

Assessing Medication Adherence on the ARMS at Week 2. (Pilot Trial B)

时间窗: Week 2 of Pilot Trial B

ARMS is a validated self-reported medication-adherence scale intended for patients with chronic diseases. Its 12 questions consist of 2 subscales - adherence to refilling prescriptions and adherence with taking medications. Each item is structured using the Likert scale, with the following response options and corresponding scores: "none" (score of 1), "some" (score of 2), "most" (score of 3 ), or "all of the time" (score of 4). The range of possible total scores is 12 to 48. Lower scores indicate better adherence.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Impact of Bilingual Prescription Medication Labels... | 临床试验